Form 4: Crinetics Chief Medical Officer Sells Shares

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, sold 6,492 shares of common stock for $29.18 per share.

Summary

• Dana Pizzuti, the Chief Medical and Development Officer of Crinetics Pharmaceuticals, Inc. (CRNX), reported a sale of common stock.
• The transaction involved the disposition of 6,492 shares of Crinetics Pharmaceuticals common stock.
• The shares were sold at a volume-weighted average price of $29.18 per share.
• The sale occurred on August 20, 2025.
• This transaction was executed automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2025.
• Following the reported transaction, Dana Pizzuti directly beneficially owns 66,270 shares of common stock.
• The reported beneficial ownership includes 529 shares acquired under the Issuer's Employee Stock Purchase Plan.
• The range of sales prices on the transaction date was between $28.94 and $29.47 per share.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, which is a routine event for executives managing their personal finances and not typically indicative of a change in company outlook or performance. Therefore, the sentiment is neutral.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider transaction, specifically a pre-planned sale of shares by an executive. Such transactions are common across all industries, including biotechnology, as executives manage personal finances. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in insider ownership, but given it's a planned transaction, it is unlikely to significantly impact shareholder confidence or perception of management's commitment.

Key Dates

Recommendation

This is a routine, pre-planned insider sale under a 10b5-1 plan. Such transactions are typically for personal financial management and do not usually signal a change in the company's fundamental prospects. Therefore, it does not provide a strong basis for a change in investment recommendation, warranting a 'hold' stance.

Keywords

Crinetics Pharmaceuticals, CRNX, Insider Sale, Form 4, Dana Pizzuti, 10b5-1 Plan, Biotechnology, Pharmaceuticals